, Tracking Stock Market Picks
Enter Symbol:
Rigel Pharmaceuticals, Inc. (RIGL) [hlAlert]

down 70.98 %

Rigel Pharmaceuticals, Inc. (RIGL) rated Buy

Posted on: Wednesday,  Oct 24, 2007  9:25 AM ET by CIBC Wrld Mkts

CIBC Wrld Mkts rated Buy Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) on 10/24/2007, when the stock price was $9.89.
Since then, Rigel Pharmaceuticals, Inc. has lost 70.98% as of 01/21/2016's recent price of $2.87.
If you would have followed this CIBC Wrld Mkts's recommendation on RIGL, you would have lost 70.98% of your investment in 3011 days.

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

CIBC World Markets strives to deliver leading edge investment research to investing clients through our multi-faceted, firm-wide research product offering. Our research has consistently been recognized as a top research source for its breadth of coverage, industry knowledge and quality of work in generating profitable and timely investment ideas. We provide in-depth coverage for all of the major sectors of the Canadian economy and select coverage of U.S. companies. Our analytical teams remain committed to identifying trends early and developing exploitable investment opportunities across the market capitalization spectrum. With the continued growth in quantitative and computerized investing strategies, we have also developed leading edge quantitative and technical research products to partner with our fundamental approach. Our products are available through several automated avenues: email, website, and third-party market vendors. Client service is our driving force and we constantly advance in offering greater product customization options.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2007 9:25 AM Buy
9.89 16.00
as of 8/27/2015
1 Week up  1.77 %
1 Month down  -16.32 %
3 Months down  -31.66 %
1 YTD up  0.70 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy